CLLD7 Polyclonal Antibody BT-AP01984
Specifications
| 20ul / 50ul / 100ul |
Background:
RCBTB1 (RCC1 and BTB domain containing protein 1) encodes a protein with an N-terminal RCC1 domain and a C-terminal BTB (broad complex, tramtrack and bric-a-brac) domain. In rat, over-expression of RCBTB1 in vascular smooth muscle cells induced cellular hypertrophy. In rat, the C-terminus of RCBTB1 interacts with the angiotensin II receptor-1A. In humans, RCBTB1 maps to a region of chromosome 13q that is frequently deleted in B-cell chronic lymphocytic leukemia and other lymphoid malignancies.
Classification:
Primary antibody
Alternative names:
RCBTB1; CLLD7; E4.5; RCC1 and BTB domain-containing protein 1; Chronic lymphocytic leukemia deletion region gene 7 protein; CLL deletion region gene 7 protein; Regulator of chromosome condensation and
Species reactivity:
Human;Mouse
Host:
Rabbit
Isotype:
IgG
Immunogen:
The antiserum was produced against synthesized peptide derived from human RCBTB1. AA range:251-300
Concentration:
1 mg/ml
Molecular weight:
58252
Applications:
WB, IHC-p, ELISA
Storage:
-20°C for one year
More info:
Email: info@sobekbio.com
Orders:
Email: orders@sobekbio.com
Fine Biotech is an ISO9001:2008 Certified Company,offers a full line of quality research kits,which include ELISA Kits,related ELISA assistant reagents and more high quality antibodies, recombinant proteins. Fine Biotech technical support are delicated to providing with professional and friendly assistance for our customers. Strict and multiple quality control ensure that our products continue to successfully supply for the international market. Moreover, we strive to continuously improve the customer experience through comprehensive technical support. High quality,rapid turnaround and personal support for all FineTest services are guaranteed. Should you have any problems,or any ideas on ways that we can improve our service,please feel free to call upon us.Thank you for your interest in FineTest products and we look forward to supplying you in the near future.